SmPC stands for Summary of Product Characteristics. It is the legally approved document that tells European healthcare professionals how to use a specific medicine safely and effectively, agreed with the regulator as part of marketing authorisation and kept updated throughout the medicine's life.
Clinical evidence tools built around US workflows often prioritize FDA materials. European healthcare professionals also need the product information approved for their own jurisdiction. For centrally authorized medicines, the European Medicines Agency publishes that information on the medicine page in a document that includes the SmPC.
The difference is not cosmetic. Authorized indications, age groups, contraindications, warnings, and conditions of use can differ between jurisdictions. A European evidence review should therefore make the applicable European source easy to identify.
What the SmPC contains
The EMA describes the SmPC as the basis of information for healthcare professionals on how to use a medicine safely and effectively. It covers the approved conditions of use, including indications, posology, contraindications, warnings, interactions, pregnancy and lactation, undesirable effects, and pharmacological properties.
SmPCs are kept updated during the lifecycle of a medicine as efficacy and safety information changes. They do not replace independent comparative research, but they are authoritative for questions about the approved European product information.
How CliniAtlas uses EMA sources today
CliniAtlas uses a curated EMA medicine registry to route relevant regulatory questions and return official EPAR and product-information links alongside literature results. The current prototype does not claim to maintain a complete full-text index of every SmPC.
This narrower approach is intentional and inspectable: identify the relevant European medicine record, show the official source, and let the reader open the current regulator-published document. Future structured ingestion can expand coverage without pretending that a partial registry is already comprehensive.
Common questions about the SmPC
- What does SmPC stand for?
- Summary of Product Characteristics. It is sometimes written SPC, though that abbreviation collides with other medical terms, so SmPC is preferred in European regulatory usage.
- Is the SmPC the same as the package leaflet?
- No. The package leaflet (PIL) is written for patients in plain language. The SmPC is the technical document for healthcare professionals, and the leaflet is prepared from it. The two must stay consistent, but they serve different readers.
- Where can I find a medicine's SmPC?
- For centrally authorised medicines, on the medicine's page at the European Medicines Agency, inside the product information document. Nationally authorised medicines are published by national regulators. In the UK, SmPCs are published on the electronic medicines compendium (emc).
- Is the SmPC evidence?
- It is authoritative for the approved conditions of use in Europe: indications, dosing, contraindications, warnings, and interactions. It is not a substitute for comparative research, but for questions about what is actually approved, it is the primary source.